Product image of Janeo (Sitagliptin) supplied by GNH India

Janeo

Active Ingredient:
Sitagliptin
Origin:
EU

Janeo (Sitagliptin)

Sitagliptin, the active ingredient in Janeo, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by enhancing incretin activity, helping regulate blood glucose levels and is used as part of a comprehensive diabetes management plan.

GNH India supplies Janeo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU Good Manufacturing Practice and provides regulatory‑compliant documentation for importers.

Manufacturer / TM Owner

Demo Abee

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion.

  • Type 2 diabetes mellitus: improves glycemic control when added to diet, exercise and other antidiabetic agents.
  • Adults inadequately controlled on metformin alone: provides additional HbA1c reduction.
  • Patients requiring once‑daily oral therapy: offers convenient dosing with a low risk of hypoglycemia when used as monotherapy.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of the incretin hormones GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells, leading to reduced hepatic glucose production and improved post‑prandial glucose control.

Side Effects

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Nausea
  • Headache
  • Nasopharyngitis
  • Upper respiratory tract infection
  • Diarrhea

Serious or Rare Side Effects

  • Pancreatitis
  • Severe allergic reactions (e.g., Stevens‑Johnson syndrome)
  • Joint pain
  • Bullous skin eruption
  • Severe hypoglycemia when combined with insulin or sulfonylureas
  • Hepatic injury

Precautions & Warnings

When prescribing or dispensing sitagliptin, several safety considerations should be observed.

  • Renal impairment: dose adjustment may be required.
  • Hepatic impairment: use with caution and monitor liver function.
  • Concomitant insulin or sulfonylureas: increased risk of hypoglycemia.
  • Pregnancy and lactation: safety not established; avoid unless clearly needed.
  • Monitor blood glucose regularly: adjust therapy based on glycemic response.
  • Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Sitagliptin can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Co‑administration with other DPP‑4 inhibitors (e.g., saxagliptin) – additive DPP‑4 inhibition.
  • Combination with insulin secretagogues (e.g., sulfonylureas) – heightened hypoglycemia risk.
  • Use with drugs known to cause pancreatitis (e.g., GLP‑1 analogues) – may exacerbate pancreatic inflammation.

Moderate Interactions (Monitor Closely)

  • CYP2C8 substrates (e.g., rosiglitazone) – possible increased exposure.
  • Diuretics (e.g., thiazides) – may affect glucose control.
  • Warfarin – monitor INR for potential interaction.

Frequently Asked Questions

Janeo contains sitagliptin, which is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It is used as part of a comprehensive treatment plan that includes diet, exercise and, when needed, other antidiabetic agents.

Sitagliptin blocks the DPP‑4 enzyme, raising levels of the incretin hormones GLP‑1 and GIP. Higher incretin concentrations stimulate insulin release only when glucose is elevated and suppress glucagon, thereby lowering blood sugar after meals.

The dose of Janeo is individualized by the prescribing healthcare professional based on the patient’s renal function, glycemic targets and any concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Janeo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Janeo belongs to the DPP‑4 inhibitor class, which offers oral once‑daily dosing and a low intrinsic risk of hypoglycemia compared with sulfonylureas. Unlike insulin or GLP‑1 receptor agonists, it does not require injection, but its glucose‑lowering effect is modest and often used in combination with metformin or other agents.

Janeo tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Janeo is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not split, crushed or chewed unless specifically instructed.

Serious adverse events include pancreatitis, severe allergic reactions such as Stevens‑Johnson syndrome, and rare cases of hepatic injury. Patients should seek immediate medical attention if they develop persistent abdominal pain, rash, blistering skin lesions or signs of liver dysfunction.

Janeo should be avoided in patients with a known hypersensitivity to sitagliptin or any component of the formulation, in those with a history of pancreatitis, and in individuals with severe renal impairment where dosing cannot be safely adjusted.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT